1. Scrip
  2. >>Therapy Areas
  3. >>Sensory

PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis

 
• By Emily Hayes

Phase III PANORAMA looks good, so far, for Regeneron's Eylea in diabetic retinopathy without edema.

Render illustration of Clinical Trial title on medical documents

Topline results for Regeneron Pharmaceuticals Inc.'sinjectable VEGF inhibitor Eylea in the Phase III PANORAMA study of diabetic retinopathy without edema pave the way for the drug to match US FDA labeling of Roche's competing Lucentis in this indication, yet the commercial value is unclear.

Eylea (aflibercept), which is partnered in Europe with Bayer AG, has been approved since 2011 in the US, where...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.